Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE no for CML drugs follows Glivec price increase

This article was originally published in Scrip

Executive Summary

NICE, the health technology appraisal institute for England and Wales, has said a preliminary "no" to Bristol-Myers Squibb's Sprycel (dasatinib), Novartis' Tasigna (nilotinib) and high-dose Glivec (imatinib) for treating chronic myeloid leukaemia (CML) that is resistant to standard-dose imatinib, because of what it said was weak evidence supporting the drugs' effectiveness and doubts about the economic models put forward. The "no" also follows an increase in the cost of Glivec.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts